Navigation Links
Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
Date:6/29/2009

Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the SFDA and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking s
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lotus Pharmaceuticals, Inc. to Exhibit at the 2009 International Conference for Bioeconomy
2. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software
5. Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
6. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
7. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
8. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
9. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
10. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... may have found a way to delay or even ... neurons with the anti-aging protein Klotho can prevent neuron ... and glutamate. These findings currently appear in the ... is the most frequent age-related dementia affecting 5.4 million ... older and more than 40 percent of people over ...
(Date:7/24/2014)... -- Drinking caffeine may worsen the hot flashes and ... they go through menopause, new survey data suggests. ... limiting caffeine intake may be useful for those postmenopausal ... said researcher Dr. Stephanie Faubion, director of the Women,s ... But caffeine -- a stimulant found in coffee ...
(Date:7/24/2014)... Bonheur Children,s Hospital and the University of Tennessee Health ... a new drug shown to safely reduce the viral ... infected with respiratory syncytial virus (RSV). RSV is the ... young children in the United States and worldwide. ... Disease Specialist John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab ...
(Date:7/24/2014)... 2014 As the age of marriage ... freezing as a way to ensure future family building ... with advancing reproductive age. Vitrification technology, a fast freeze ... medical technology that allows a woman to have multiple ... years, which are then stored for future use. When ...
(Date:7/24/2014)... 24, 2014 In a recent report by ... officially put an end to criminal penalties associated with possession ... era for marijuana reform in Washington DC, giving it one ... law replaces criminal penalties for possession of one ounce of ... the possession of more than an ounce of marijuana remain ...
Breaking Medicine News(10 mins):Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:RSV research breakthrough to help infected children 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4Health News:Washington D.C. Decriminalizes Marijuana 2
... for more careful screening for these patients, researcher says ... with metabolic syndrome have a 75 percent higher risk ... new study suggests. , "Metabolic syndrome is a conglomeration ... a worse prognosis for certain illnesses, including a number ...
... a protein that plays matchmaker between two key types ... them to interact in a way that is crucial ... finding may also explain why some individuals who have ... proteincalled SAPsuffer from lethal infections with a common virus ...
... The Johns Hopkins University School,of Medicine is ... Cancer Strategies: From Biomarkers to Treatment,Selection," to present ... in,breast cancer treatment., In recent years, advancements ... chemotherapeutic and biologic treatment combinations that are,increasingly tailored ...
... Molecular CT adds metabolic information from PET to traditional ... for maximized workflow ... and quick return on investment, MUNICH, Germany, Oct. ... a new concept in,integrated imaging that provides a premium ...
... This may sound like,science fiction, but it is truly ... become the first U.S. doctor,licensed to provide TA-65 to ... Beach, Florida., This is a revolutionary technology that ... DNA. They are located at the ends of all ...
... Oct. 9 After a thorough review of ... (VDSS),announced that it has selected Policy Studies Inc. ... the Chesapeake and Hampton districts.,PSI is a leading ... The contract is valued at approximately $7 million ...
Cached Medicine News:Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:NIH scientists discover crucial control in long-lasting immunity 2Health News:NIH scientists discover crucial control in long-lasting immunity 3Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4Health News:Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging 2Health News:Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging 3Health News:PSI Selected to Operate Virginia's Child Support Program in Chesapeake and Hampton 2
(Date:7/24/2014)... BUFFALO, N.Y. , July 24, 2014  Kinex ... US FDA for the Company,s KX2-391 Ointment for the ... keratosis. This is the Company,s third IND to be ... months. KX2-391 is a synthetic, orally active ... and tubulin polymerization. KX2-391 promotes the induction of p53, ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Monitoring Market by Product, Component, Application and Geography - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... expected to witness a moderate growth as the markets ... have almost reached the saturation levels. The demand is ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- "North America Orthopedic Braces ... data on the North America Orthopedic Braces and Supports ... dollars, and volume (in units) and average price data ... Knee Braces and Supports , Ankle Braces and ... Upper Extremities Braces and Supports. ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
... Nov. 7, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... 30, 2011. Total revenue was $2.6 million and $8.2 ... compared to $1.3 million and $3.8 million for the same periods ... nine months ended September 30, 2011, were $9.0 million and $24.0 ...
... CHICAGO, Nov. 7, 2011 UCB today announced findings ... rates to Cimzia ® (certolizumab pegol) plus methotrexate ... effect on structural joint damage in patients with moderate ... responses were found by both RAPID3 (Routine Assessment of ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 2New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 3New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 4New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 5New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 6New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 7New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 8New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 10New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 11New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 12
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
... for cystometry and urethral pressure profilometry. ... faster filling of the bladder and ... lumen catheter construction allows the bladder ... performed. Triple lumen catheter construction allows ...
... with AMI symptoms and time is ... rapid, reliable and accurate solution for ... enhancement techniques, state-of-the-art fluorescence analysis, and ... delivers highly sensitive results without compromising ...
... Capillary Blood Collection Tubes are 100% plastic ... wide range of applications, the Capillary Collection ... attached cap and a micro tube.,The capillary ... blood into the micro tube thereby eliminating ...
Medicine Products: